Cargando…

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges

Immunization against amyloid-β (Aβ) peptides deposited in Alzheimer’s disease (AD) has shown considerable therapeutic effect in animal models however, the translation into human Alzheimer’s patients is challenging. In recent years, a number of promising Aβ immunotherapy trials failed to reach primar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cynis, Holger, Frost, Jeffrey L., Crehan, Helen, Lemere, Cynthia A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929720/ https://www.ncbi.nlm.nih.gov/pubmed/27363697 http://dx.doi.org/10.1186/s13024-016-0115-2

Ejemplares similares

Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study
por: Frost, Jeffrey L., et al.
Publicado: (2012)

Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice
por: Crehan, Helen, et al.
Publicado: (2020)

N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity
por: Kehlen, Astrid, et al.
Publicado: (2017)

Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
por: Wirths, Oliver, et al.
Publicado: (2009)

Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease
por: Bayer, Thomas A.
Publicado: (2021)

Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration
por: Becker, Andreas, et al.
Publicado: (2013)

Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2011)

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
por: Perez-Garmendia, Roxanna, et al.
Publicado: (2013)

Immunotherapy for Alzheimer’s disease: hoops and hurdles
por: Lemere, Cynthia A
Publicado: (2013)

Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
por: Schilling, Stephan, et al.
Publicado: (2018)

Activity and Architecture of Pyroglutamate-Modified Amyloid-β (Aβ(pE3-42)) Pores
por: Gillman, Alan L., et al.
Publicado: (2014)

Structural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous Trifluoroethanol
por: Dammers, Christina, et al.
Publicado: (2015)

Solid-phase synthesis and pathological evaluation of pyroglutamate amyloid-β(3-42) peptide
por: Cho, Illhwan, et al.
Publicado: (2023)

Metabolic Acidosis Due To Pyroglutamic Acid
por: Serpa, Maria João, et al.
Publicado: (2018)

Flucloxacillin and paracetamol induced pyroglutamic acidosis
por: Zand Irani, Anis, et al.
Publicado: (2021)

Role of the Fast Kinetics of Pyroglutamate-Modified Amyloid-β Oligomers in Membrane Binding and Membrane Permeability
por: Lee, Joon, et al.
Publicado: (2014)

Modulation of aggregation and structural polymorphisms of β-amyloid fibrils in cellular environments by pyroglutamate-3 variant cross-seeding
por: Cruceta, Letticia, et al.
Publicado: (2023)

4,4′-Bipyridine–pyroglutamic acid (1/2)
por: Arman, Hadi D., et al.
Publicado: (2009)

Pyroglutamic Acidosis – An Underrecognised Entity Associated with Acetaminophen Use
por: Ng, Wincy Wing-Sze, et al.
Publicado: (2023)

Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Aβ pathology at the lysosome
por: De Kimpe, Line, et al.
Publicado: (2012)

Pyroglutamic acidosis as a cause for high anion gap metabolic acidosis: a prospective study
por: Spector, Shir Raibman, et al.
Publicado: (2019)

The Bacteroidetes Q-Rule: Pyroglutamate in Signal Peptidase I Substrates
por: Bochtler, Matthias, et al.
Publicado: (2018)

Pyroglutamate-modified Aβ(3-42) affects aggregation kinetics of Aβ(1-42) by accelerating primary and secondary pathways
por: Dammers, C., et al.
Publicado: (2017)

Long‐term patterns of urinary pyroglutamic acid in healthy humans
por: Lord, Richard S.
Publicado: (2016)

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
por: Moro, Maria Luisa, et al.
Publicado: (2018)

5-oxoprolinuria (Pyroglutamic Aciduria) and Metabolic Acidosis: Unraveling the Mystery
por: Senthilkumaran, Subramanian, et al.
Publicado: (2019)

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice
por: Dunkelmann, Tina, et al.
Publicado: (2018)

Is Pyroglutamic Acid a Prognostic Factor Among Patients with Suspected Infection? A Prospective Cohort Study
por: Gueta, Itai, et al.
Publicado: (2020)

Postmortem Neocortical (3)H-PiB Binding and Levels of Unmodified and Pyroglutamate Aβ in Down Syndrome and Sporadic Alzheimer’s Disease
por: Pivtoraiko, Violetta N., et al.
Publicado: (2021)

Synergistic Effect on Neurodegeneration by N-Truncated Aβ(4−42) and Pyroglutamate Aβ(3−42) in a Mouse Model of Alzheimer's Disease
por: Lopez-Noguerola, Jose S., et al.
Publicado: (2018)

Publisher Correction: Pyroglutamic acidosis as a cause for high anion gap metabolic acidosis: a prospective study
por: Raibman Spector, Shir, et al.
Publicado: (2020)

An unusual cause of high anion gap metabolic acidosis: pyroglutamic acidosis
por: Wardell, RJ, et al.
Publicado: (2012)

Pyroglutamic acidosis by glutathione regeneration blockage in critical patients with septic shock
por: Gamarra, Yenifer, et al.
Publicado: (2019)

Acquired pyroglutamic acidosis due to long-term dicloxacillin and paracetamol use
por: Zand Irani, Anis, et al.
Publicado: (2020)

Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation
por: Li, Zhiqiang, et al.
Publicado: (2021)

Molecular Mechanism of L-Pyroglutamic Acid Interaction with the Human Sour Receptor
por: Eom, Sanung, et al.
Publicado: (2023)

Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
por: Antonios, Gregory, et al.
Publicado: (2015)

Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy
por: Dammers, Christina, et al.
Publicado: (2015)

Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer’s disease and related murine models
por: Neddens, Joerg, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1ue2vdbdnoeqk5eh70s6t936nh